Thank you! My journey to founding HLTH Communications wasn’t a straight line. It was more much more like a zigzag that eventually pointed to a clear purpose. I began my career in capital markets, working a boutique investment bank and later working with private as well as public companies raise capital, go public and help […]

The biotech sector has always thrived on storytelling. A compelling narrative can attract capital, energize researchers and capture the public imagination long before a drug makes it to market. But after years of market volatility and overpromises, I’ve noticed many investors are approaching new pitches with sharper scrutiny than ever.

There’s a first time for everything, and now is the time for Enveric Biosciences to submit its first-ever IND to the FDA. After forgoing a Phase 1 in Australia and deciding to out-license that asset, Enveric now finds itself facing its first IND submission. This time, they’re seeking the OK for EB-003, a novel neuroplastogen […]

Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned.

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been viewed as a fringe pursuit, scientifically intriguing, but clinically and commercially fraught. AbbVie’s decision to pay up for access to Gilgamesh’s pipeline marked a clear […]

With many groundbreaking discoveries waiting to be made and innovative solutions being developed, the biotechnology industry provides many rewarding career opportunities for individuals who want to make a meaningful impact on people’s lives. So, if you are searching for a job in the field, we have highlighted eight biotechnology careers that are not only in […]

When AbbVie reportedly agreed to acquire Gilgamesh Pharmaceuticals in a deal valued at over $1 billion, it sent a clear signal to the market: big pharma is betting on psychedelics. The acquisition validated the growing interest in compounds designed to treat psychiatric disorders by promoting neuroplasticity. It also underscored a crucial shift in the field, from […]

Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. In this article, we take a look at six of the top psychedelic companies leading their particular niches in the field of psychedelic medicines.

Psychedelic drugs have been on quite the trip. Though they have been used culturally for thousands of years for medicinal and spiritual reasons—from psilocybin-containing mushrooms in Aztec rituals to the iboga plant used by Bwiti shaman in Africa and indigenous Amazonian groups using ayahuasca—their entry into modern chemistry and Western medicine didn’t begin until the […]

As global capital markets brace for uncertainty, the current administration’s tariff policies have introduced a new wave of volatility—sending a ripple effect across sectors and borders. While tariffs have long been used as a geopolitical tool, their resurgence in 2025 can be disruptive for startups and growth-stage companies that rely on market stability and investor […]